Floatz logo

Rasburicase

Hematopoietic and Lymphoid Cell Neoplasm

M.D. Anderson Cancer Centerprotein_peptidePhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hematopoietic and Lymphoid Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
FILGRASTIM
St. Jude Children's Research Hospital
Phase 2BB
Pegloticase
M.D. Anderson Cancer Center
Phase 4BB
Fludarabine
National Cancer Institute (NCI)
Phase 3BB
CYCLOSPORIN A
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

Rasburicase is also rated in:

tumor lysis syndromeDormant
A
Indicative ·
80 / 100
View asset →
neoplasmDormant
BB
Indicative ·
67 / 100
View asset →
lymphomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →